FDA approves 1st immunotherapy drug to treat breast cancer

 


The U.S. Food and Drug Administration has approved the first immunotherapy drug for breast cancer.

Swiss drugmaker Roche's Tecentriq was OK'd Friday for treating advanced triple-negative breast cancer, which accounts for about 15 percent of cases. It's to be given with chemotherapy, the standard treatment.

Mount Sinai breast cancer specialist Dr. Amy Tiersten in New York called it "tremendously exciting news."

Approved for two other cancers, Tecentriq works by boosting the immune system's ability to spot and kill cancer cells.

In a study of 900 women, the benefits were modest. Those who rec...



For access to this article please sign in or subscribe.

 

Reader Comments(0)

 
 

Our Family of Publications Includes:

Arc
Newsgram

Powered by ROAR Online Publication Software from Lions Light Corporation
© Copyright 2024